Sgmo stock rating
Wedbush Reiterates Hold Rating for Sangamo Therapeutics ... Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “hold” rating reiterated by Wedbush in a report issued on Wednesday, TipRanks reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock. Wedbush’s price objective would indicate a potential upside of 23.00% from the company’s current price. Sangamo Therapeutics Shows Promise - RealMoney In the daily bar chart of SGMO, below, we can see that the stock has been trading lower the past 12 months but declines have been followed by steep recovery rallies. TheStreet Ratings updates
Sangamo Therapeutics Inc (SGMO) News | Morningstar
Sangamo Therapeutics, Inc. (SGMO) Quant Ratings | Seeking ... An overall objective rating for Sangamo Therapeutics, Inc. (SGMO) optimized for predictive value. Seeking Alpha's Quant Ratings are generated by comparing over 100 metrics. HC Wainwright Reaffirms Buy Rating for Sangamo ... HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report issued on Monday morning, AnalystRatings.com reports. HC Wainwright currently has a $16.00 target price on the biopharmaceutical company’s stock. SGMO has been the subject of several other reports. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a buy rating […]
SGMO - Sangamo Therapeutics Stock Analyst Ratings ...
In depth view into SGMO (Sangamo Therapeutics) stock including the latest price Target on Sangamo Therapeutics to $10 From $11, Maintains Neutral Rating. ConsumerFeed, @ConsumerFeed. Sangamo Therapeutics $SGMO Stock Rating Upgraded by ValuEngine https://t.co/5gW9XwVGen. April 5th 2020, 11:04am 4 days ago Sangamo Therapeutics, Inc. (SGMO) Social Stream. SGMO Home Add SGMO to Watchlist See all "A" rated Strong Buy stocks. Loading Detailed price information for Sangamo Therapeutics (SGMO-Q) from The Globe and Mail including charting and trades. Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Stock Reports +.
16 Mar 2020 (NASDAQ: SGMO) The 36 Months beta value for SGMO stocks is at 2.17, while of the analysts out of 0 who provided ratings for Sangamo
26 Mar 2020 Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SGMO Sangamo Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. 16 Mar 2020 (NASDAQ: SGMO) The 36 Months beta value for SGMO stocks is at 2.17, while of the analysts out of 0 who provided ratings for Sangamo Sangamo Therapeutics Inc (SGMO) Stock Quote and detailed dividend history in the field below to get our experts' instant Bull/Bear rating, ranking & more.
Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, ValuEngine reports. Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “strong-buy” rating and set a […]
Sangamo Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. SGMO updated stock price target summary. Dow Jones, a News Corp company. SGMO Stock Price, Forecast & News (Sangamo Therapeutics) Analyzing Sangamo Therapeutics (NASDAQ:SGMO) stock? View SGMO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Sangamo Therapeutics Inc Stock Quote: SGMO Stock News ... Nov 01, 2019 · SGMO, Sangamo Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Sangamo Therapeutics - SGMO - Stock Price & News | The ...
JPM - SGMO: Another ZFN Win with BIIB Collaboration ... Mar 02, 2020 · It is rare to see a large firm like JP Morgan place a Neutral rating on a stock that requires almost 65% appreciation to hit the target. My comments are devoid of any comments about the fair value of SGMO. Long-term holders will be handsomely rewarded over time with many shots on goals across an exceptionally diverse portfolio and prospective Cowen & Co. Maintains Their Buy Rating on Sangamo ...